Deep search
Profile Picture
  • All
  • Search
  • Images
  • Videos
  • Maps
  • News
  • Copilot
  • More
    • Shopping
    • Flights
    • Travel
  • Notebook
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days
  • Best match
    • Most recent

News

Thoma Bravo to buy Verint in $2 billion deal

Yahoo Finance · 3h
Thoma Bravo to acquire Verint for $2bn
The deal will facilitate the merger of Verint with Thoma Bravo's Calabrio, a provider of CX intelligence solutions.
Reuters on MSN · 21h
Thoma Bravo to buy Verint in $2 billion deal as software acquisitions ramp up
Thoma Bravo will acquire Verint Systems in a $2 billion deal, including debt, the customer engagement platform said on Monday, marking the latest software buyout as private equity firms increasingly bet on AI to navigate an uncertain economy.
The Wall Street Journal on MSN · 23h
Thoma Bravo to Buy Verint for $2 Billion
Thoma Bravo has agreed to buy call center software company Verint for $20.50 a share in an all-cash transaction.
The Fast Mode
10h

Thoma Bravo to Acquire Verint for $2B, Merge with Calabrio to Lead CX Automation Market

Thoma Bravo, a leading software investment firm, announced that it has entered into a definitive agreement to purchase Verint ...
2d

Olo: Strong Growth Justifies Thoma Bravo's $2B Buyout, But Upside Is Capped

Olo's Q2 2025 highlights 22% revenue growth & Thoma Bravo's $2B buyout with a 65% premium. Explore its growth potential & ...
6d

Thoma Bravo secures leeway from backers to hand slice of PE deals to other investors

Private equity group Thoma Bravo secured carte blanche from backers of its latest funds for it to allocate a cut of buyout deals to other investors, in the latest sign of how some firms are adapting ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results
Feedback
© 2025 Microsoft
  • Privacy and Cookies
  • Legal
  • Advertise
  • About our ads
  • Help
  • Feedback
  • Your Privacy Choices
  • Consumer Health Privacy